Celyad Oncology S.A.
CYAD
Classificação em ações
#31891
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Preço da ação
$0.24706331
Valor de mercado
$11.68M
Variação (1 dia)
-0.81%
Variação (1 ano)
-14.91%
País
BE
Negociar Celyad Oncology S.A. (CYAD)
Categoria
Healthcare
Histórico de desdobramentos de ações de Celyad Oncology S.A. (CYAD)
As ações Celyad Oncology S.A. (símbolo: CYAD) passaram por um total de 0 desdobramentos.
O desdobramento mais recente ocorreu em Oct 21, 2026.
Uma ação CYAD comprada antes de Oct 21, 2026 equivaleria hoje a 0 ações CYAD.
O desdobramento mais recente ocorreu em Oct 21, 2026.
Uma ação CYAD comprada antes de Oct 21, 2026 equivaleria hoje a 0 ações CYAD.
Lista de desdobramentos de ações
| Ano | Desdobramento | Multiplicador | Multiplicador cumulativo |
|---|---|---|---|
| Não há dados suficientes para as datas fornecidas. | |||
Desdobramentos de ações de empresas semelhantes ou concorrentes
| Empresa | Número de desdobramentos de ações | Multiplicador cumulativo | País |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
